Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder

ClinicalTrials.gov ID: NCT06340958

Public ClinicalTrials.gov record NCT06340958. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Design, Phase 2 Study to Assess the Efficacy and Safety of CLE-100 as an Adjunctive Treatment for Major Depressive Disorder Patients With Inadequate Response to Standard Antidepressants

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study is a Phase 2, double-blind, randomized, placebo-controlled study in Major Depressive Disorder (MDD) participants with an inadequate response to standard antidepressants The objective of the study is to assess CLE-100 (oral esketamine) for the treatment of MDD in participants currently treated with an oral antidepressant medication and who have an inadequate response to at least 2 antidepressants.

Study identification

NCT ID
NCT06340958
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Clexio Biosciences Ltd.
Industry
Enrollment
99 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 17, 2024
Primary completion
Jun 5, 2025
Completion
Nov 24, 2025
Last update posted
Jun 22, 2026

2024 – 2025

United States locations

U.S. sites
23
U.S. states
13
U.S. cities
23
Facility City State ZIP Site status
Clinical Site 139 La Jolla California 92037
Clinical Site 131 Lafayette California 94549
Clinical Site 130 Upland California 91786
Clinical Site 102 Hollywood Florida 33024
Clinical Site 105 Lauderhill Florida 33319
Clinical Site 140 Miami Springs Florida 33166
Clinical Site 132 Pensacola Florida 32502
Clinical Site 118 Atlanta Georgia 30030
Clinical Site 138 Marietta Georgia 30060
Clinical Site 114 Savannah Georgia 31405
Clinical Site 127 Chicago Illinois 60640
Clinical Site 120 Elgin Illinois 60123
Clinical Site 108 Gaithersburg Maryland 20877
Clinical Site 116 Flowood Mississippi 39232
Clinical Site 126 O'Fallon Missouri 63368
Clinical Site 101 Toms River New Jersey 08755
Clinical Site 103 Beachwood Ohio 44236
Clinical Site 119 North Canton Ohio 44720
Clinical Site 135 Oklahoma City Oklahoma 73112
Clinical Site 107 Austin Texas 78737
Clinical Site 137 Plano Texas 75093
Clinical Site 117 Murray Utah 84107
Clinical Site 115 Bellevue Washington 98007

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06340958, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 22, 2026 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06340958 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →